BeiGene Announces Clinical Results on Tislelizumab Presented at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)
/EIN News/ -- BEIJING, China and CAMBRIDGE, Mass., Sept. 22, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and Commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced clinical results on its investigational anti-PD-1 antibody tislelizumab from three ongoing clinical trials in China. These new or updated data were presented in five of the seven Oral presentations on tislelizumab at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), taking place September 18-22, 2019 in Xiamen, China. Additional BeiGene clinical data being presented at CSCO include four poster presentations on tislelizumab, zanubrutinib, And pamiparib.
"Taken together these data show the potential for tislelizumab to benefit patients across a number of indications where we see unmet need in China and around the world," said Yong (Ben) Ben, MD, Chief Medical Officer, Immuno-Oncology at BeiGene. "In anticipation of our first regulatory approvals in China for tislelizumab in classical Hodgkin's lymphoma and urothelial carcinoma, we are nearing the first stage of completion on our state-of-the art biologics manufacturing facility, which we expect will be a model for quality biologics Manufacturing operations at a global scale."作者: StephenW 时间: 2019-9-23 13:19
百济神州宣布在中国临床肿瘤学会（CSCO）第22届年会上发表的Tislelizumab的临床结果
/ EIN News /-中国北京和马萨诸塞州剑桥（2019年9月22日）商业化用于治疗癌症的分子靶向和免疫肿瘤药物的创新性，今天宣布了其在中国进行的三项临床试验中其抗PD-1抗体tislelizumab的临床研究结果。在2019年9月18日至22日在中国厦门举行的中国临床肿瘤学会（CSCO）第22届年会上，关于替雷利珠单抗的七次口服报告中有五次介绍了这些新数据或更新数据。在CSCO上展示的另外的百济神州临床数据包括关于tislelizumab，zanubrutinib和pamiparib的四个海报展示。